Karishma Bhatia Mehta, MD
Pulmonary Disease · Las Vegas, NVNPI 1598174351
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,051 of the $1,749 with a category attached, or 60.1%. 13 manufacturers reported payments, led by Intuitive Surgical at 51.1% of the total. Reporting peaked in 2021 at $852 and has fallen 80.7% since, to $164 in 2025. That places this record below the midpoint for pulmonary disease clinicians in NV, where the typical reported total is $1,728.
Across 31 payments — averaging $56.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$894
- Body Vision Medical Inc.$155
- Boehringer Ingelheim$143
- Merck$120
- Inspire Medical Systems, Inc.$107
- AstraZeneca$99
- plus $229 from 7 others
What the payments were for
- Travel & lodging$69740%
- Food & beverage$1,05160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $894 |
| Body Vision Medical Inc. | 1 | $155 |
| Boehringer Ingelheim | 2 | $143 |
| Merck | 1 | $120 |
| Inspire Medical Systems, Inc. | 1 | $107 |
| AstraZeneca | 1 | $99 |
| Electromed, Inc. | 12 | $86 |
| Exelixis Inc. | 1 | $50 |
| Bristol Myers Squibb | 1 | $22 |
| Pfizer | 1 | $21 |
| Philips North America LLC | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$668
- LungVision$155
- OFEV$125
- WINREVAIR$120
- Inspire$107
How this compares
$1,749 in reported general payments places this provider in the 50th percentile of 84 pulmonary disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 341 | $358,017 |
| OfevNintedanib Esylate | 24 | $311,736 |
| OpsumitMacitentan | 11 | $140,945 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $101,846 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 104 | $96,650 |
| Dupixent PenDupilumab | 13 | $50,182 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $39,563 |
| Spiriva RespimatTiotropium Bromide | 43 | $34,861 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 33 | $28,715 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 59 | $14,086 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $12,542 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $11,231 |
| Incruse ElliptaUmeclidinium Bromide | 23 | $11,031 |
| Wixela InhubFluticasone Propion/Salmeterol | 63 | $10,770 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $8,851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $143 | $375,313100 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $99 | $105,501129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 84 pulmonary disease providers in Nevada.
Other pulmonary disease in Las Vegas
- Arthur RomeroLas Vegas$310K
- Lloyd DelmundoLas Vegas$150K
- Naresh SinghLas Vegas$111K
- Abhishek KumarLas Vegas$74K
- Jerome HruskaLas Vegas$72K
- Vishisht MehtaLas Vegas$22K
- Kamran KhanLas Vegas$17K
- John WojcikLas Vegas$14K
- Walter WilloughbyLas Vegas$10K
- Robert LampertLas Vegas$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.